Filing Flows

Filing Flows › CVS Health (CVS) › Stock forecast & fair value

CVS Health (CVS) stock forecast and fair value

CVS Health (CVS) trades at $81.33. 25 analysts' median price target is $113.00 (+39%), from $86.00 to $146.00. Across 24 valuation methods the middle fair value is $147.78 (+82%); the DCF says $168.20.

Price$81.33
Median target$113.00
Fair value, middle$147.78
DCF$168.20
EPS beat rate100%
CVS Health fair value by method (price $81.33)CVS Health fair value by method (price $81.33)low – highpoint estimateRegime-switching Monte Carlo 10th–9…$314.25DCF — Monte Carlo 10th–90th percent…$168.20P/E vs peers$171.35P/E vs peers, weighted$179.58EV/EBITDA vs peers$147.87EV/EBITDA vs peers, weighted$169.01EV/Sales vs peers$274.74EV/Sales vs peers, weighted$370.05EV/Sales vs peers, growth & margin …$206.26Residual income$75.14

Fair value by method

MethodLowPointHighvs price
Regime-switching Monte Carlo 10th–90th−$48.73$314.25$828.62+286%
DCF — Monte Carlo 10th–90th percentile$15.95$168.20$347.36+107%
P/E vs peers$106.05$171.35$223.19+111%
P/E vs peers, weighted$130.44$179.58$272.18+121%
EV/EBITDA vs peers$74.42$147.87$253.11+82%
EV/EBITDA vs peers, weighted$92.49$169.01$225.51+108%
EV/Sales vs peers$175.70$274.74$492.20+238%
EV/Sales vs peers, weighted$210.13$370.05$655.03+355%
EV/Sales vs peers, growth & margin adjusted$120.37$206.26$339.45+154%
Residual income$72.39$75.14$78.05-8%

CVS Health's latest quarter

CVS Health, Q3 2026: revenue $108.4B (+5% year over year), operating margin 3.3%, net earnings $2.2B, operating cash flow $4.7B. The chart follows the revenue to costs, profit and cash.

Questions

What is the price target for CVS stock?

The median of 25 analysts' 12-month targets is $113.00, +39% from $81.33; the range is $86.00 to $146.00. The average rating is strong buy.

What is CVS Health's fair value?

The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $46.20 and $370.05, with a middle value of $147.78 against a price of $81.33. Each method's assumptions are on the page.

Does CVS Health usually beat earnings estimates?

It beat the consensus EPS estimate in 100% of the quarters on record.

Is CVS stock a buy?

Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.